| http://www.w3.org/ns/prov#value | - As RPTCs are characterized and better understood, the data used could potentially shift toward pathway analyses, with a decreased reliance on in vivo data.A WoE evaluation for risk assessment also needs to consider variables such as exposure, which will require the use of dosimetry, reverse dosimetry, and biomonitoring.
|
